← Issue №18/ week of Nov 1, 2026/ the whole section, in full

Endoscopy, in full.

All 9 Endoscopy papers in this issue, as full cards, ranked by clinical utility. The issue page carries the strongest few; this is the section, whole.

Sections this issue
Filter

All 9, in full

most clinically useful first · the 1 the issue led with is ruled in green
Endoscopy prospective cohort · n=1,023 · Oct 30, 2026 · GIE · IF 8.0

Prospective multicenter evaluation of aceto-electronic chromoendoscopy added to Narrow-Band Imaging for real-time identification of deep submucosal invasion in colorectal polyps.

New evidencecolonoscopypolypectomycomputer-aided detectioncolorectal cancer
Clinical takeawayConsider using AEC in addition to M-NBI for real-time optical diagnosis of deep submucosal invasion in colorectal polyps ≥10 mm, particularly when deep invasion is suspected.
What it foundAdding aceto-electronic chromoendoscopy (AEC) to magnifying narrow-band imaging (M-NBI) improved specificity for deep submucosal invasion from 56.9% to 74.5% and overall accuracy from 60.3% to 77.6% (P < .0001).
ContextThis study refines current practice by demonstrating that AEC enhances the diagnostic accuracy of M-NBI, reducing overdiagnosis and improving specificity in identifying T1b lesions.
Measured against the standard of care· USMSTF 2020 (Shaukat et al.) / AGA Clinical Practice Update Commentary 2025 (Ngamruengphong et al.), created from: AGA Clinical Practice Update on Endoscopic Resection for Early Colorectal Cancer: Commentary (2025), https://doi.org/10.1053/j.gastro.2025.09.001

For colorectal lesions suspected to contain early (T1) cancer, US practice follows the USMSTF 2020 guideline on malignant colorectal polyps, with the AGA 2025 Clinical Practice Update commentary added on top. Management starts with a careful endoscopic assessment for features of deep submucosal invasion (for example, NICE type 3 or excavated morphology). … A nonpedunculated lesion at high risk of superficial submucosal invasion should be removed en bloc, with proper specimen handling. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

For colorectal lesions suspected to contain early (T1) cancer, US practice follows the USMSTF 2020 guideline on malignant colorectal polyps, with the AGA 2025 Clinical Practice Update commentary added on top. Management starts with a careful endoscopic assessment for features of deep submucosal invasion (for example, NICE type 3 or excavated morphology). A nonpedunculated lesion with deep-invasion features should be biopsied and tattooed, then referred for surgical resection. The AGA 2025 commentary adds that endoscopic local excision, including endoscopic full-thickness resection for selected T1 lesions under 2 cm, can be considered where technically feasible. A nonpedunculated lesion at high risk of superficial submucosal invasion should be removed en bloc, with proper specimen handling. ESD is often preferred to EMR because it achieves higher en bloc rates. Piecemeal resection of a suspected cancer is discouraged: it compromises histologic staging and independently predicts recurrence, and NCCN treats a T1 cancer removed piecemeal as needing surgery. After complete endoscopic removal of a malignant polyp, whether to recommend surgery depends on polyp shape, whether en bloc resection and an adequate histologic assessment were achieved, unfavorable histologic features (lymph node metastasis risk), surgical risk, and patient preference. The AGA 2025 commentary advises referral to a high-volume center with endoscopic resection and pathology expertise when the diagnosis is unclear and suspicion for cancer is high. It also advises expert GI pathology review and multidisciplinary discussion of resected T1 specimens. Lesions resected en bloc with no unfavorable histology can be managed with endoscopic surveillance instead of surgery.

USMSTF 2020 (Shaukat et al.) / AGA Clinical Practice Update Commentary 2025 (Ngamruengphong et al.), created from: AGA Clinical Practice Update on Endoscopic Resection for Early Colorectal Cancer: Commentary (2025), https://doi.org/10.1053/j.gastro.2025.09.001 · reviewed 2026-10-11 ↗
Yamamoto S … Kodama T · Gastrointestinal Endoscopy · IF 8.0 · PubMed ↗Permalink
Endoscopy rct · n=266 · Oct 28, 2026 · Clin Gastro Hep · IF 16.2

Real-time Voice-Guided Artificial Intelligence Improves Biliopancreatic Endosonography Quality: A Randomized Trial.

New evidenceartificial intelligenceEUSendoscopy qualitycomputer-aided detection
Clinical takeawayConsider using AI-assisted EUS (EUS-GUIDEQ) to improve adherence to guideline-recommended biliopancreatic scanning stations, particularly in settings where completeness is a priority, while accounting for the modest increase in procedure time.
What it foundAI-assisted EUS (EUS-GUIDEQ) improved station completeness to 1.00 (IQR 0.94-1.00) vs 0.81 (IQR 0.75-0.88) with standard EUS (P<0.001), but increased procedure time by 2.15 minutes. No serious procedure-related adverse events occurred.
ContextConfirms the potential of AI to enhance procedural quality in EUS, addressing known variability in operator adherence to guideline-recommended scanning protocols in adult patients undergoing biliopancreatic EUS.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Wang R … Wang X · Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association · IF 16.2 · PubMed ↗Permalink
Endoscopy rct · n=248 · Oct 26, 2026 · J Clin Gastro · IF 2.9

Distributed Sample Allocation for the Diagnosis of Mass Lesions by EUS-FNA: A Prospective, Multicenter, Randomized Controlled Study.

New evidenceEUSendoscopy qualitycomputer-aided detection
Clinical takeawayConsider using distributed sample allocation during EUS-FNA procedures to improve diagnostic accuracy, particularly for mediastinal/lung lesions and cystic solid lesions. Ensure proper training and protocol adherence for optimal implementation.
What it foundDistributed sample allocation raised EUS-FNA diagnostic accuracy from 88.31% to 96.34% (P=0.0262), with notable improvement in mediastinal/lung lesions (P=0.0128) and cystic solid lesions (P=0.0235).
ContextThis study introduces a novel approach to EUS-FNA sample handling, refining current practice by optimizing diagnostic accuracy through distributed sample allocation. The findings are particularly relevant for patients with mediastinal/lung lesions and cystic solid lesions.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Han C … Lin R · Journal of Clinical Gastroenterology · IF 2.9 · PubMed ↗Permalink
Endoscopy retrospective · n=128 · Oct 30, 2026 · GIE · IF 8.0

Comparative Effectiveness of Two Novel Anti-Migration Strategies in Fully Covered Self-Expandable Metal Stents for Biliary Strictures: A Multicenter Propensity-Matched Study.

New evidencebiliary strictureERCPendoscopy qualitytranslational
Clinical takeawayConsider FCSEMS-AF over FCSEMS-AB for biliary strictures when migration risk is a priority, and FCSEMS-AB when occlusion risk is higher, based on findings from a multicenter retrospective cohort study.
What it foundFCSEMS-AB had 5.25x higher odds of migration vs FCSEMS-AF (aOR 5.25, 95% CI 1.58-17.49) but 0.27x lower odds of occlusion (aOR 0.27, 95% CI 0.10-0.78).
ContextChallenges prior assumptions about anti-migration designs by showing a trade-off between migration resistance and occlusion risk in patients with biliary strictures.
Measured against the standard of care· ESGE 2026 (biliary stricture management; replaces ESGE 2018 stenting guideline) / ESGE 2025 (biliary stricture diagnosis)

… A fully covered SEMS (FCSEMS) is an option only if the stricture is more than 2 cm below the hepatic confluence or the patient will not comply with repeated ERCPs. … Use plastic stents when the drainage strategy is undefined or the centre is not expert. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Diagnosis is unchanged and still follows the separate ESGE diagnostic guideline (Endoscopy 2025;57:166-185). Start with MRI/MRCP plus laboratory tests, read CA19-9 only after decompression, and check IgG4 when IgG4-related sclerosing cholangitis is suspected. For distal extrahepatic strictures with no pancreatic mass, do combined same-session EUS-guided tissue acquisition plus ERCP brushing and biopsy. For perihilar strictures, sample by ERCP first and move to cholangioscopy-guided biopsy if the result is indeterminate. Do not place an uncovered SEMS (USEMS) until malignancy is confirmed. Management now follows the 2026 ESGE biliary stricture management guideline, which replaces the 2018 stenting guideline and brings it into line with the 2022 therapeutic EUS guideline. Benign: post-cholecystectomy strictures get temporary multiple plastic stents (MPSs), exchanged every 3-4 months with as many stents as possible, for about 12 months. A fully covered SEMS (FCSEMS) is an option only if the stricture is more than 2 cm below the hepatic confluence or the patient will not comply with repeated ERCPs. Anastomotic strictures after liver transplant get MPSs, or a temporary FCSEMS if more than 2 cm below the confluence. Nonanastomotic post-transplant strictures that can be treated endoscopically get MPSs plus balloon dilation if needed. Chronic pancreatitis strictures get a temporary 8-10 mm FCSEMS for 6-12 months. High-grade PSC strictures get balloon dilation alone, with no stent, because stenting adds no benefit and may add adverse events. Endotherapy is indicated for a benign stricture with liver tests raised for more than 1 month and/or cholangitis. Malignant distal: drain before surgery only selectively (cholangitis, severe jaundice or pruritus, delayed surgery). When drainage is needed before surgery or neoadjuvant therapy, or for palliation, place a 10-mm SEMS endoscopically. Endoscopic drainage is preferred over surgery or PTBD for inoperable obstruction. Malignant hilar: manage in high-volume centres with a hepatobiliary multidisciplinary team (MDT). ERCP is preferred over PTBD for preoperative drainage. Palliate Bismuth I-II with ERCP. For Bismuth III-IV, ERCP or ERCP combined with EUS-guided drainage (EUS-BD) is preferred over primary PTBD, with PTBD as a complement if needed. For proven Bismuth II-IV, aim to drain more than 50%, ideally 70% or more, of the viable nonatrophic liver volume using several routes as needed. Use plastic stents when the drainage strategy is undefined or the centre is not expert. USEMS are for expert centres when the diagnosis is proven, the tumour is unresectable, and complete drainage is predicted. After failed or unfeasible ERCP, EUS-BD is recommended over PTBD. Use hepaticogastrostomy (EUS-HGS) if there is a duodenal stricture, and EUS-HGS or choledochoduodenostomy (EUS-CDS) if there is not. PTBD is used if EUS-BD fails. In surgically altered anatomy, benign disease gets enteroscopy-assisted ERCP first; malignant disease gets enteroscopy-assisted ERCP or EUS-BD. Give antibiotics before ERCP in selected cases: predicted incomplete drainage, hilar strictures, immunocompromised patients, PSC, cholangioscopy. This follows the ESGE ERCP-adverse-events guideline. Etiology-specific care (Strasberg injuries, IgG4-SC, Mirizzi, choledochal cysts) is unchanged.

ESGE 2026 (biliary stricture management; replaces ESGE 2018 stenting guideline) / ESGE 2025 (biliary stricture diagnosis) · reviewed 2026-10-11 ↗
Ramai D … Ko C · Gastrointestinal Endoscopy · IF 8.0 · PubMed ↗Permalink
Endoscopy rct · n=60 · Oct 29, 2026 · Dig Liver Dis · IF 4.2

Comparing precutting endoscopic band ligation-assisted resection vs ESD for small gastric SMTs: a randomized controlled trial.

New evidenceESDEMRcost-effectivenessendoscopy quality
Clinical takeawayPrecutting EBLR may be considered as a faster and cost-effective alternative to ESD for small gastric SMTs ≤ 16 mm, particularly in non-academic or lower-volume centers, pending further validation.
What it foundPrecutting EBLR reduced median operation time to 17.5 min compared to 30 min for ESD in gSMT-MP ≤ 16 mm.
ContextOffers a potential alternative to ESD for small gastric SMTs ≤ 16 mm, with shorter operation times and lower costs, though further validation is needed.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Zhou Y … Deng L · Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · IF 4.2 · PubMed ↗Permalink
Endoscopy review · Oct 31, 2026 · Dig Liver Dis · IF 4.2

The changing role of the gastroenterologist in the management of advanced gastric cancer.

Guideline / reviewbiomarkerendoscopy quality
Clinical takeawayEnsure adequate endoscopic sampling for reliable molecular profiling and collaborate with pathologists and oncologists to standardize biomarker assessment and therapeutic allocation, addressing challenges like tumor heterogeneity and testing variability.
What it foundBiomarker-driven strategies, including HER2, PD-L1, MSI/MMR deficiency, Claudin-18.2, and emerging targets like FGFR2b and EBV status, guide targeted therapies and immune checkpoint inhibitors in advanced gastric cancer.
ContextConfirms the critical role of gastroenterologists in obtaining representative tumor tissue for biomarker-driven treatment decisions, emphasizing the importance of multidisciplinary collaboration and addressing challenges like spatial and temporal tumor heterogeneity, limited tissue availability, and variability in testing methods.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Cannizzaro R … Pinto C · Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · IF 4.2 · PubMed ↗Permalink
Endoscopy rct · n=38 · Oct 30, 2026 · J Neurogastro Motil · IF 3.4

Reflux and Other Esophageal Acidification Patterns in Achalasia Patients With Reflux Esophagitis After Peroral Endoscopic Myotomy.

New evidenceachalasiaesophageal motility
Clinical takeawayIn post-POEM esophagitis, acid exposure time did not separate patients with and without esophagitis (14.5% vs 6.0%, P=0.64); this 38-patient study describes patterns and tests no treatment.
What it foundPatients with reflux esophagitis grade B-D after POEM had lower minimum pH (1.5 vs. 2.1, P = 0.024) and longer supine reflux episodes (7.7% vs. 0.0%, P = 0.041).
ContextConfirms that supine reflux with delayed clearance is a key pattern in post-POEM reflux esophagitis, refining understanding of GERD mechanisms in patients with reflux esophagitis grade B-D.
Emergingsuggested applicable standard· American College of Gastroenterology (ACG), Vaezi MF, Pandolfino JE, Yadlapati RH, Greer KB, Kavitt RT. "ACG Clinical Guidelines: Diagnosis and Management of Achalasia." Am J Gastroenterol. 2020 Sep;115(9):1393-1411. doi:10.14309/ajg.0000000000000731

… TREATMENT: pneumatic dilation is superior to medical therapy for symptom relief and esophageal emptying (strong, very low). … When surgical myotomy is performed, add fundoplication: myotomy with fundoplication is superior to myotomy alone for controlling distal esophageal acid exposure (strong, moderate), using either Dor or Toupet (conditional, moderate). …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text. The rest of this standard includes FOLLOW-UP, RETREATMENT, SURVEILLANCE.

Our full summary of this standard

Evaluate for achalasia any patient with dysphagia to solids and liquids, regurgitation, or chest pain, and specifically consider it in patients presumed to have GERD who do not respond to acid suppression (strong recommendation, very low quality). Diagnose with high-resolution manometry using esophageal pressure topography rather than conventional line tracings (strong, high). Subtype by Chicago Classification (I, II, III), this is a conditional recommendation (low quality): subtyping may inform prognosis and treatment choice, with type II having the most favorable outcomes and type III requiring a longer/tailored myotomy; ACG does not make subtyping mandatory for diagnosis. Always perform upper endoscopy in suspected achalasia to exclude pseudoachalasia from an obstructing mass; use cross-sectional imaging and/or endoscopic ultrasound in difficult cases (ACG states this as narrative guidance, not a numbered recommendation, and specifies no biopsy protocol). FLIP is described as complementary, useful in patients who cannot tolerate manometry and as an arbiter in difficult cases where manometry fails to diagnose achalasia despite high clinical suspicion, not as a required confirmatory test. TREATMENT: pneumatic dilation is superior to medical therapy for symptom relief and esophageal emptying (strong, very low). PD and laparoscopic Heller myotomy are both effective and equivalent short- and long-term for patients who are candidates for definitive therapy (strong, high). POEM and LHM give comparable symptomatic improvement (strong, moderate). POEM and PD give comparable symptomatic improvement in type I or II (conditional, low). For type III, tailored POEM or LHM is recommended as a more efficacious disruptive LES therapy than PD (strong, moderate), ACG does NOT single out POEM over LHM for type III. When surgical myotomy is performed, add fundoplication: myotomy with fundoplication is superior to myotomy alone for controlling distal esophageal acid exposure (strong, moderate), using either Dor or Toupet (conditional, moderate). Botulinum toxin injection is first-line therapy for patients unfit for definitive therapy (strong, moderate), and prior botulinum toxin does not significantly compromise subsequent myotomy performance or outcomes (strong, low). POEM carries a higher incidence of GERD than LHM with fundoplication or PD (strong, moderate). Do not place stents for long-term dysphagia (strong, low). Reserve esophagectomy for surgically fit patients with megaesophagus who have failed other interventions (strong, low), and consider Heller myotomy before esophagectomy in patients who failed PD and POEM when the anatomy is conducive and there is evidence of incomplete myotomy (strong, very low). FOLLOW-UP: use timed barium esophagram as the first-line test to evaluate continued or recurrent symptoms after definitive therapy (strong, very low); the Eckardt score alone or HRM alone should not be used to define treatment failure. Do not obtain routine gastrografin esophagram after dilation, reserve it for clinical suspicion of perforation (strong, low). RETREATMENT: PD is appropriate and safe after failed surgical myotomy or POEM (strong, moderate), and POEM is safe in patients who previously underwent PD or LHM (strong, low). SURVEILLANCE: ACG recommends AGAINST routine endoscopic surveillance for esophageal carcinoma in patients with achalasia (strong, low), although risk is elevated (~1 cancer per 300 patient-years), absolute numbers are low, an estimated >400 endoscopies would be needed to detect one cancer, and surveillance has not demonstrated improved survival.

American College of Gastroenterology (ACG), Vaezi MF, Pandolfino JE, Yadlapati RH, Greer KB, Kavitt RT. "ACG Clinical Guidelines: Diagnosis and Management of Achalasia." Am J Gastroenterol. 2020 Sep;115(9):1393-1411. doi:10.14309/ajg.0000000000000731 · reviewed 2026-07-19 ↗
Wessels EM … Bredenoord AJ · Journal of Neurogastroenterology and Motility · IF 3.4 · PubMed ↗Permalink
Endoscopy meta analysis · Oct 27, 2026 · Eur J Gastro Hep · IF 2.2

Comparison of diagnostic performance of 19-gauge versus 22-gauge fine-needle biopsy needles for endoscopic ultrasound-guided liver biopsy: a systematic review and meta-analysis.

New evidenceEUSmeta-analysisbiomarkersystematic review
Clinical takeawayConsider 19G needles for EUS-LB when longer specimen length is prioritized, but expect similar diagnostic yield and safety compared to 22G needles in adult patients undergoing EUS-LB.
What it found19G needles yielded longer aggregate specimen length (ASL) and longest fragment length than 22G needles, but no significant differences in diagnostic yield, tissue adequacy, adverse events, or complete portal tracts compared to 22G needles.
ContextConfirms prior variability in EUS-LB needle outcomes, clarifying that 19G needles offer longer specimens without compromising diagnostic yield or safety compared to 22G needles.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Saeed A … Kamal F · European Journal of Gastroenterology & Hepatology · IF 2.2 · PubMed ↗Permalink
Endoscopy review · Oct 27, 2026 · Am J Gastro · IF 9.8

Prevention and Management of Electrocautery-enhanced Lumen-apposing Metal Stent (EC-LAMS) Complications.

Guideline / reviewERCPEUShemostasis
Clinical takeawayConsider EC-LAMS complications when planning procedures and implement procedure-specific preventive measures, especially in high-risk settings such as pancreatic necrosectomy and Roux-en-Y gastric bypass anatomy.
What it foundEC-LAMS complications occur in up to 20% of patients, with misdeployment, bleeding, peritoneal leak, stent occlusion, and migration being common.
ContextConfirms the known high complication rate of EC-LAMS, emphasizing the need for careful patient selection and procedural expertise in high-volume referral centers.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Ansari Z … Trieu JA · American Journal of Gastroenterology · IF 9.8 · PubMed ↗Permalink
← Back to issue №18 Every section of this issue is one click away, at the top of this page. Follow Endoscopy by RSS